Elacestrant Hydrochloride
FDA-approved product (tablet, oral), marketed as Orserdu.
- Registered studies
- 2
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Breast neoplasm
- Male breast carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Anti-estrogens
- FDA pharmacologic class
- Estrogen Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA54.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis38.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
2registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Elacestrant Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
NCT07467772 · start 2026-03-25
Registered record
- Registry ID
- NCT07467772
- Conditions
- Uterine Sarcoma; Uterine Leiomyosarcoma; Endometrial Stromal Sarcoma; ESS; Perivascular Epithelioid Cell Tumors; Uterine Adenosarcoma; Uterine PEComa; Estrogen Receptor Positive Tumor; uLMS
- Interventions
- Elacestrant
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-03-25
- Completion
- 2028-04
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUterine Sarcoma; Uterine Leiomyosarcoma; Endometrial Stromal Sarcoma; ESS +5 moreInterventionElacestrantPhasePhase 2Registry statusRecruitingPhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
NCT07222215 · start 2026-01-16
Registered record
- Registry ID
- NCT07222215
- Conditions
- Estrogen-receptor-positive Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Hormone Receptor Positive Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2- Breast Cancer; ESR1 Gene Mutation; ER Wildtype; Breast Neoplasms
- Interventions
- Capecitabine; Elacestrant
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-01-16
- Completion
- 2030-10-01
- Enrolment
- 297
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEstrogen-receptor-positive Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Hormone Receptor Positive Breast Cancer +5 moreInterventionCapecitabine; ElacestrantPhasePhase 2Registry statusRecruiting